RNAZ TRANSCODE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, TRANSCODE THERAPEUTICS INC reported revenue of n/a, net income of −$6.75M and diluted EPS of −$7.17; for the fiscal year ended December 2025 revenue was n/a.
RNAZ annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$28.0M, net income −$34.7M (margin n/a), EPS −$52.59
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$15.7M, net income −$16.8M (margin n/a), EPS −$1336.63
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$19.4M, net income −$18.5M (margin n/a), EPS −$3419.01
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$18.6M, net income −$17.6M (margin n/a), EPS −$1082.79
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$6.15M, net income −$6.84M (margin n/a), EPS −$0.81
RNAZ quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.75M, EPS −$7.17
- Quarter ended Mar 31, 2026: revenue n/a, net income −$17.8M, EPS −$21.28
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$13.4M, EPS $28.52
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.86M, EPS −$5.82
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.28M, EPS −$5.13
- Quarter ended Mar 31, 2025: revenue n/a, net income −$12.1M, EPS −$70.16
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$5.92M, EPS −$488.99
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.32M, EPS −$146.06
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.19M, EPS −$680.23
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.33M, EPS −$21.35
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.09M, EPS −$2969.12
- Quarter ended Sep 30, 2023: revenue n/a, net income −$5.30M, EPS −$48.44
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.34M, EPS −$142.38
- Quarter ended Mar 31, 2023: revenue n/a, net income −$4.82M, EPS −$259.07
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.13M, EPS −$1068.71
- Quarter ended Sep 30, 2022: revenue n/a, net income −$4.29M, EPS −$6.61
- Quarter ended Jun 30, 2022: revenue n/a, net income −$4.67M, EPS −$7.20
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.47M, EPS −$0.27
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.80M, EPS −$0.15
- Quarter ended Sep 30, 2021: revenue n/a, net income −$2.33M, EPS −$0.20
RNAZ cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$19.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$13.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$18.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$15.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$5.27M, share buybacks n/a
RNAZ balance sheet
- Jun 30, 2026: cash $8.38M, total assets $151M, total liabilities $12.7M, shareholders' equity −$27.7M
- Mar 31, 2026: cash $12.8M, total assets $157M, total liabilities $12.6M, shareholders' equity $1.25M
- Dec 31, 2025: cash $17.8M, total assets $162M, total liabilities $10.5M, shareholders' equity $10.3M
- Sep 30, 2025: cash $2.84M, total assets $5.23M, total liabilities $3.80M, shareholders' equity $1.43M
- Jun 30, 2025: cash $7.37M, total assets $8.27M, total liabilities $2.12M, shareholders' equity $6.15M
- Mar 31, 2025: cash $11.6M, total assets $13.2M, total liabilities $2.90M, shareholders' equity $10.3M
- Dec 31, 2024: cash $5.81M, total assets $7.29M, total liabilities $9.31M, shareholders' equity −$2.02M
- Sep 30, 2024: cash $1.88M, total assets $3.94M, total liabilities $2.28M, shareholders' equity $1.65M
Is RNAZ profitable?
No. TRANSCODE THERAPEUTICS INC lost $42.8M over the last four quarters.
What is RNAZ's EPS?
Diluted earnings per share over the last four quarters were −$5.75; −$7.17 in the latest quarter.